Diagnostic and Therapeutic Endoscopy / 2016 / Article / Tab 2

Clinical Study

Therapeutic Endoscopy Can Be Performed Safely in an Ambulatory Surgical Center: A Multicenter, Prospective Study

Table 2

Indications, findings, and interventions for inpatient versus ASC ERCP, EUS, and the total population.

⁢ERCPEUSTotal
INASCALL (95% CI)INASCALL (95% CI)INASCALL (95% CI)

Indications
Biliary
 Obstructive jaundice39 (51%)37 (23%)76 (32%)0.000510 (46%)8 (7%)18 (13%)0.0749 (50%)45 (16%)94 (25%)<0.0001
 SOD24 (32%)40 (25%)64 (27%)0.023 (14%)8 (7%)11 (8%)0.9827 (28%)48 (17%)75 (20%)0.02
 Dilated biliary ductal system31 (41%)25 (16%)56 (24%)<0.00014 (18%)5 (4%)9 (7%)0.9435 (36%)30 (11%)65 (17%)0.003
 Choledocholithiasis19 (25%)22 (14%)41 (17%)0.0460001.0019 (19%)22 (8%)41 (11%)0.55
 Elevated LFT17 (20%)5 (3%)22 (9%)0.00023 (14%)1 (1%)4 (3%)1.0020 (20%)6 (2%)26 (7%)0.004
 Cholangitis9 (12%)09 (4%)0.920001.009 (9%)10 (3%)9 (2%)1.00
 Biliary stricture3 (4%)8 (5%)11 (5%)0.371 (5%)1 (1%)2 (1%)0.994 (4%)9 (3%)13 (4%)0.62
 Stent extraction9 (12%)28 (18%)37 (16%)0.121 (5%)01 (1%)0.9910 (10%)28 (10%)38 (10%)0.03
 Bile leak10 (13%)14 (9%)24 (10%)0.531 (5%)01 (1%)0.9811 (11%)14 (5%)25 (7%)0.35
Pancreatic
 Pancreatic mass8 (11%)10 (6%)18 (8%)0.096 (27%)26 (22%)32 (23%)0.1914 (14%)36 (13%)50 (13%)<0.0001
 Pancreatic cyst06 (4%)6 (3%)0.961 (5%)38 (33%)39 (28%)0.221 (1%)44 (16%)45 (12%)<0.0001
 Chronic pancreatitis2 (3%)16 (10%)18 (8%)0.111 (5%)8 (7%)9 (7%)0.373 (3%)24 (9%)27 (7%)0.48
 Gall stone pancreatitis11 (15%)1 (1%)12 (5%)0.0033 (14%)3 (3%)6 (3%)0.0214 (14%)4 (1%)18 (5%)0.009
 Pancreatic divisum1 (1%)10 (6%)11 (5%)0.1102 (2%)2 (1%)0.991 (1%)14 (5%)15 (4%)0.44
Neoplastic
 Any neoplasm11 (15%)12 (8%)23 (10%)0.103 (14%)29 (25%)32 (23%)0.6121 (21%)44 (16%)65 (17%)<0.0001
 Palliation neoplasm5 (7%)1 (1%)6 (3%)0.062 (9%)02 (1%)1.007 (7%)1 (1%)8 (2%)0.50
 Staging of neoplasm6 (8%)6 (4%)12 (5%)0.685 (23%)46 (39%)51 (37%)0.9811 (11%)52 (19%)63 (17%)<0.0001
Generalized
 Chronic abdominal pain8 (11%)53 (33%)61 (26%)0.000406 (5%)6 (3%)0.998 (8%)59 (21%)67 (18%)<0.0001
Intervention
ERCP
 Biliary
  EBS57 (75%)108 (68%)165 (70%)<0.0001NA1.0057 (58%)108 (39%)165 (44%)<0.0001
  Needle knife1 (1%)1 (1%)2 (1%)1.00NA1.001 (1%)1 (1%)2 (1%)1.00
  SEMS12 (16%)5 (3%)17 (8%)0.06NA1.0012 (12%)5 (2%)17 (5%)0.06
  Plastic stent23 (30%)18 (11%)41 (17%)0.003NA1.0023 (24%)18 (7%)41 (11%)0.003
  Cytology11 (15%)22 (14%)33 (14%)0.0002NA1.0011 (1%)22 (8%)33 (9%)0.0002
  Cholangioscopy4 (5%)11 (7%)15 (11%)0.40NA1.004 (4%)11 (4%)15 (4%)0.40
  Manometry2 (3%)18 (11%)20 (9%)0.47NA1.002 (2%)18 (7%)20 (5%)0.47
 Pancreatic
  EPS6 (8%)30 (19%)36 (15%)0.03NA1.006 (6%)30 (11%)36 (10%)0.03
  Minor duct papillotomy1 (1%)8 (5%)9 (4%)0.92NA1.001 (1%)8 (3%)9 (2%)0.92
  PD Stent21 (28%)44 (28%)65 (28%)1.00NA1.0021 (21%)44 (16%)65 (17%)0.60
 Ampullary biopsy2 (3%)13 (8%)15 (6%)0.1301 (1%)1 (1%)1.003 (3%)14 (5%)17 (5%)0.81
EUS
 FNANA1.0012 (55%)77 (66%)89 (64%)<0.000112 (12%)77 (28%)89 (24%)<0.0001

ERCP: endoscopic retrograde cholangiopancreatography; EUS: endoscopic ultrasound; IN: inpatients; ASC: ambulatory surgical center patients; ALL: inpatients + ASC patients; GI: gastrointestinal; LFT: liver function tests; SOD: sphincter of Oddi dysfunction; GIST: gastrointestinal stromal tumor; IPMN: intraductal papillary mucinous neoplasm; NE: neuroendocrine; EBS: endoscopic biliary sphincterotomy; EPS: endoscopic pancreatic sphincterotomy; SEMS: self-expanding metal stent; FNA: fine needle aspiration.
Note that is significant.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.